secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2022-01-24T23:59:59+00:00
Accession:  0001104659-22-006977
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte preliminary Q4 rev >$10M (+17% YoY); FY rev >$33.7M (+28%); adds 4 SPLs in 2021
--------------------------------------------------------------------------------

- Q4 2021 preliminary revenue >$10.0M (up from $8.5M in Q4 2020); core business revenue grew at least 37%.
- Full year 2021 revenue >$33.7M (up from $26.2M in 2020); program-related revenue $2.5M (vs $3.3M in 2020).
- Installed base grew to >500 instruments (from >400); 15 SPLs covering >95 programs, over 15% in clinic.
- Precommercial milestone potential from SPLs exceeds $1.25B (up from >$950M in 2020).
- New SPLs: Nkarta, Myeloid Therapeutics, Celularity, Sana Biotechnology; ExPERT VLx instrument launched.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465922006977/0001104659-22-006977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465922006977/tm224229d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-006977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer